Last reviewed · How we verify

NCT04969952

Evaluation of an Interventional Module to Assist Physicians Introducing ACP to Cancer Patients

Completed NA Last updated 18 June 2024
What this trial tests

NA trial testing For interventional module in Cancer Patients in 384 participants. Completed in 20 December 2023.

Timeline
6 April 2021
Primary endpoint
20 September 2023
20 December 2023

Quick facts

Lead sponsorNational Taiwan University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment384
Start date6 April 2021
Primary completion20 September 2023
Estimated completion20 December 2023
Sites2 locations across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 85, any sex, with Cancer Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of an Interventional module to assist physicians introducing ACP to cancer patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer Patients

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing